Seo Ja Young, Hong Junshik, Chun Kayeong, Jeong Jihoon, Cho Hyeongrae, Kim Kyung Hee, Park Jinny, Ahn Jeong Yeal, Park Pil-Whan, Lee Jae Hoon
a Department of Laboratory Medicine, Gachon University Gil Medical Center, Incheon Regional Cancer Center , Gachon University College of Medicine , Incheon , Republic of Korea.
b Department of Internal Medicine, Gachon University Gil Medical Center , Incheon Regional Cancer Center, Gachon University College of Medicine , Incheon , Republic of Korea.
Leuk Lymphoma. 2017 Feb;58(2):357-365. doi: 10.1080/10428194.2016.1190967. Epub 2016 Jun 9.
The prognostic role of detecting clonal immunoglobulin gene rearrangement (IgR) from bone marrow (BM) aspirates was evaluated by BIOMED-2 PCR in 97 patients with diffuse large B-cell lymphoma (DLBCL) treated with rituximab-CHOP immunochemotherapy. Sixteen (16.5%) patients had BM involvement (BMI) defined by BM biopsy (MOR+) and 39 (40.2%) had positive IgR (PCR+). Patients with MOR + BMI showed inferior event-free survival (EFS) compared to those with MOR-/PCR- (p < 0.001) or those with MOR-/PCR + BMI (p = 0.002), while no significant difference in EFS was observed between patients with MOR-/PCR + and those with MOR-/PCR - BMI (p = 0.497). Use of the BIOMED-2 for PCR resulted in significant increase in detection of BMI. However, the increased sensitivity by PCR did not translate into improved prediction of prognosis, emphasizing the essential role of histopathological review of trephine biopsy for the detection of BMI.
通过BIOMED-2聚合酶链反应（PCR）评估了从骨髓穿刺物中检测克隆性免疫球蛋白基因重排（IgR）在97例接受利妥昔单抗-CHOP免疫化疗的弥漫性大B细胞淋巴瘤（DLBCL）患者中的预后作用。16例（16.5%）患者经骨髓活检（MOR+）确定有骨髓受累（BMI），39例（40.2%）患者IgR呈阳性（PCR+）。与MOR-/PCR-（p<0.001）或MOR-/PCR+BMI（p=0.002）的患者相比，MOR+BMI的患者无事件生存期（EFS）较差，而MOR-/PCR+BMI与MOR-/PCR-BMI的患者之间在EFS上未观察到显著差异（p=0.497）。使用BIOMED-2进行PCR检测显著提高了BMI的检出率。然而，PCR检测敏感性的提高并未转化为对预后的更好预测，强调了骨髓活检组织病理学检查在BMI检测中的重要作用。
